影响肝母细胞瘤儿童术后生存的因素分析

doi:10.3969/j.issn.1672-5069.2016.01.030

摘要/Abstract

摘要： 目的分析影响肝母细胞瘤儿童术后生存期的因素。方法选择2003年1月~2010年3月手术治疗的肝母细胞瘤患儿76例,进行定期随访,统计术后5 a生存率,并分析其影响因素。结果本组肝母细胞瘤儿童术后5 a生存率为48.68%（37/76）;在≤2岁、血清LDH水平>240 U/L、血清CRP水平>10 mg/L患儿,5 a生存率分别为46.15%、35.90%、37.84%,明显低于>2岁、血清LDH水平≤240 U/L、血清CRP水平≤10 mg/L患儿（分别为54.16%、62.16%、58.97%）;血清AFP水平>10000 μg/L患儿5a 生存率为10.71%,明显低于<100 μg/L、100~10000μg/L患儿的68.75%、71.88%;PretextⅠ期、Ⅱ期、Ⅲ期患者5 a生存率分别为80%、55.56%、8.33%,病理分型胎儿型、胚胎型、混合型分别为60.98%、44.44%、23.53%,5 a生存率均依次减低,组间差异有统计学意义（P<0.05）;血清AFP水平、Pretext分期、病理分型是影响肝母细胞瘤儿童术后生存期的独立危险因素（OR1=4.223,OR2=5.826,OR3=9.342,P<0.05）。结论肝母细胞瘤儿童术后5 a生存期仍较低,血清AFP水平、Pretext分期和病理分型是需要重点考虑的问题。

关键词: 肝母细胞瘤, 儿童, 生存期, 影响因素

Key words: Hepatoblastoma, Children, Survival, Influencing factors

蒋文军, 曹李明, 李治熹. 影响肝母细胞瘤儿童术后生存的因素分析[J]. 实用肝脏病杂志, 2016, 19(1): 102-104.

Jiang Wenjun， Cao Liming， Li Zhixi. Factor affecting survival of children with hepatoblastoma after operation[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 102-104.

参考文献

[1] Meyers RL,Czauderna P,Otte JB. Surgical treatment of hepatoblastoma. Pediatr Blood Cancer,2012,59（5）：800-808.
[2] Ismail H,Broniszczak D,Kaliciński P,et al.Changing treatment and outcome of children with hepatoblastoma: analysis of a single center experience over the last 20 years.J Pediatr Surg,2012,47（7）：1331-1339.
[3] 张伟令,张谊,黄东生,等. 儿童晚期肝母细胞瘤综合治疗的疗效观察. 中华实用儿科临床杂志,2013,28（7）：521-524.
[4] Gupta K,Rane S,Das A,et al. Relationship of beta-catenin and postchemotherapy histopathologic changes with overall survival in patients with hepatoblastoma. J Pediatr Hematol Oncol,2012,34（8）：320-328.
[5] 胡亚美,江载芳.诸福棠实用儿科学. 7版,北京：人民卫生出版社,2002：16-42.
[6] Zsiros J,Brugieres L,Brock P,et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high risk hepatoblastoma （SIOPEL4）：a prospective,single-arm,feasibility study. Lancet Oncol,2013,14（9）：834-842.
[7] Tsay PK,Lai PK,Yang CP,et al.Treatment outcomes for hepatoblastoma：Experience of 35 cases at a single institution.J Formos Med Assoc,2011,110（5）：322-325.
[8] Arora RS.Outcomes of hepatoblastoma in the Indian context.Indian Pediatrics,2012,49（4）：307-309.
[9] Barrena S,Hernandez F,Miguel M,et al.High-risk hepatoblastoma：results in a pediatric liver transplantation center.Eur J Pediatr Surg,2011,21（1）：18-20.
[10] Sail MW,Li J,Lamb L,et al. First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second- line therapy in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol,2014,73（2）：373-380.
[11] Karski EE,Dvorak CC,Leung W,et al. Treatment of hepatoblastoma with high-dose chemotherapy and stem cell rescue:the pediatric blood and marrow transplant consortium experience and review of the literature.J Pediatr Hematol Oncol,2014,36（5）：362-368.
[12] Malogolowkin MH,Katzenstein HM,Meyers RL,et al. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology:a report from the Children's Oncology Group. J Clin Oncol,2011,29（24）：3301-3306.
[13] Von Schweinitz D.Hepatoblastoma:recent developments in research and treatment.Semin Pediatr Surg,2012,21（1）：21-30.
[14] Maibach R,Roebuck D,Brugieres L,et al. Prognostic stratification for children with hepatoblastoma:the SIOPEL experience.Eur J Cancer,2012,48（10）：1543-1549.
[15] Ueda Y,Hiyama E,Kamimatsuse A,et al.Wnt signaling and telomerase activation of hepatoblastoma:correlation with chemosensitivity and surgical respectability. J Pediatr Surg,2011,46（12）：2221-2227.
[16] 乔晓红,赵强,胡月,等. 儿童肝母细胞瘤综合治疗27例疗效探讨. 中华小儿外科杂志,2012,33（9）：647-650.
[17] 李丹妮,于新生,赵爱芝,等.影响儿童肝母细胞瘤预后的多因素分析. 中国实用儿科杂志,2013,28（2）：126-128.
[18] Koh KN,Park M,Kim BE,et al. Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma.Pediatr Blood Cancer,2011,57（4）：554-560.
[19] 吴艳梅,王珊,胡显良,等. 术前应用经导管动脉化疗栓塞治疗儿童肝母细胞瘤的疗效分析. 重庆医科大学学报,2014,39（2）：241-245.
[20] 葛军涛,李龙,乔国梁,等. 肝母细胞瘤预后评分系统的建立并比较其与常见预后模型的预测价值.中华小儿外科杂志,2015,36（1）：21-25.